• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传学、免疫和营养促进非酒精性脂肪性肝炎向肝癌的转变。

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC.

作者信息

Dongiovanni Paola, Meroni Marica, Longo Miriam, Fargion Silvia, Fracanzani Anna Ludovica

机构信息

General Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Pad. Granelli, 20122 Milan, Italy.

Department of Clinical Sciences and Community Health, Università degli Studi di Milano, 20122 Milan, Italy.

出版信息

Biomedicines. 2021 Oct 23;9(11):1524. doi: 10.3390/biomedicines9111524.

DOI:10.3390/biomedicines9111524
PMID:34829753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8614742/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading contributor to the global burden of chronic liver diseases. The phenotypic umbrella of NAFLD spans from simple and reversible steatosis to nonalcoholic steatohepatitis (NASH), which may worsen into cirrhosis and hepatocellular carcinoma (HCC). Notwithstanding, HCC may develop also in the absence of advanced fibrosis, causing a delayed time in diagnosis as a consequence of the lack of HCC screening in these patients. The precise event cascade that may precipitate NASH into HCC is intricate and it entails diverse triggers, encompassing exaggerated immune response, endoplasmic reticulum (ER) and oxidative stress, organelle derangement and DNA aberrancies. All these events may be accelerated by both genetic and environmental factors. On one side, common and rare inherited variations that affect hepatic lipid remodeling, immune microenvironment and cell survival may boost the switching from steatohepatitis to liver cancer, on the other, diet-induced dysbiosis as well as nutritional and behavioral habits may furtherly precipitate tumor onset. Therefore, dietary and lifestyle interventions aimed to restore patients' health contribute to counteract NASH progression towards HCC. Even more, the combination of therapeutic strategies with dietary advice may maximize benefits, with the pursuit to improve liver function and prolong survival.

摘要

非酒精性脂肪性肝病(NAFLD)是导致全球慢性肝病负担的主要因素。NAFLD的表型范围从简单且可逆的脂肪变性到非酒精性脂肪性肝炎(NASH),后者可能恶化为肝硬化和肝细胞癌(HCC)。尽管如此,HCC也可能在没有晚期纤维化的情况下发生,由于这些患者缺乏HCC筛查,导致诊断延迟。可能促使NASH发展为HCC的确切事件级联是复杂的,它涉及多种触发因素,包括过度的免疫反应、内质网(ER)和氧化应激、细胞器紊乱和DNA异常。所有这些事件都可能因遗传和环境因素而加速。一方面,影响肝脏脂质重塑、免疫微环境和细胞存活的常见和罕见遗传变异可能会促进从脂肪性肝炎向肝癌的转变,另一方面,饮食引起的生态失调以及营养和行为习惯可能会进一步促使肿瘤发生。因此,旨在恢复患者健康的饮食和生活方式干预有助于抵消NASH向HCC的进展。更重要的是,治疗策略与饮食建议的结合可能会使益处最大化,以追求改善肝功能和延长生存期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5233/8614742/d3e37a1b8747/biomedicines-09-01524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5233/8614742/d3e37a1b8747/biomedicines-09-01524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5233/8614742/d3e37a1b8747/biomedicines-09-01524-g001.jpg

相似文献

1
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC.遗传学、免疫和营养促进非酒精性脂肪性肝炎向肝癌的转变。
Biomedicines. 2021 Oct 23;9(11):1524. doi: 10.3390/biomedicines9111524.
2
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.利用动物模型研究非酒精性脂肪性肝炎相关的肝细胞癌。
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.
3
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.分子机制:非酒精性脂肪性肝病、脂肪性肝炎和肝细胞癌之间的联系。
Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525.
4
Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?肝细胞癌筛查与非酒精性脂肪性肝病:二者有何不同?
J Clin Exp Hepatol. 2020 Sep-Oct;10(5):518-524. doi: 10.1016/j.jceh.2020.04.004. Epub 2020 Apr 18.
5
Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.非酒精性脂肪性肝病所致肝细胞癌:当前概念与未来挑战
J Hepatocell Carcinoma. 2022 Jun 1;9:477-496. doi: 10.2147/JHC.S344559. eCollection 2022.
6
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的组织病理学
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
7
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
8
Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.膳食ω-3脂肪酸预防非酒精性脂肪性肝病及降低原发性肝癌风险的潜力。
Adv Nutr. 2015 Nov 13;6(6):694-702. doi: 10.3945/an.115.009423. Print 2015 Nov.
9
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.筛查和干预措施以预防非酒精性脂肪性肝病/非酒精性脂肪性肝炎相关肝细胞癌。
World J Gastroenterol. 2023 Jan 14;29(2):286-309. doi: 10.3748/wjg.v29.i2.286.
10
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].[非酒精性脂肪性肝病/非酒精性脂肪性肝炎管理概述]
Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.

引用本文的文献

1
DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application.DGAT1 和 DGAT2 抑制剂治疗代谢相关脂肪性肝病(MASLD):单药或联合应用的获益。
Int J Mol Sci. 2024 Aug 21;25(16):9074. doi: 10.3390/ijms25169074.
2
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.代谢功能障碍相关脂肪性肝病诱导的肝细胞癌中表观遗传学与代谢重编程之间的串扰:新视角
Metabolites. 2024 Jun 8;14(6):325. doi: 10.3390/metabo14060325.
3

本文引用的文献

1
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.TM6SF2/PNPLA3/MBOAT7 基因功能丧失性变异对非酒精性脂肪性肝病发生发展的影响:在患者和体外模型中的研究。
Cell Mol Gastroenterol Hepatol. 2022;13(3):759-788. doi: 10.1016/j.jcmgh.2021.11.007. Epub 2021 Nov 23.
2
Genetics Is of the Essence to Face NAFLD.遗传学对于应对非酒精性脂肪性肝病至关重要。
Biomedicines. 2021 Sep 30;9(10):1359. doi: 10.3390/biomedicines9101359.
3
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients.
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.
非酒精性脂肪性肝病相关肝细胞癌综述:发病机制、早期检测及治疗干预的进展
Front Med (Lausanne). 2024 Jun 4;11:1410668. doi: 10.3389/fmed.2024.1410668. eCollection 2024.
4
Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.伴有 HCC 的 MASLD 患者的心脏代谢危险因素:硬币的另一面。
Front Endocrinol (Lausanne). 2024 May 23;15:1411706. doi: 10.3389/fendo.2024.1411706. eCollection 2024.
5
Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis.非酒精性脂肪性肝炎相关肝细胞癌的研究现状与前沿:一项文献计量学与可视化分析
Front Pharmacol. 2023 Sep 12;14:1240649. doi: 10.3389/fphar.2023.1240649. eCollection 2023.
6
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis.非酒精性脂肪性肝病相关肝细胞癌:继病毒性肝炎之后的下一个威胁。
Diagnostics (Basel). 2023 Aug 9;13(16):2631. doi: 10.3390/diagnostics13162631.
7
The Role of Oxidative Stress and Cellular Senescence in the Pathogenesis of Metabolic Associated Fatty Liver Disease and Related Hepatocellular Carcinoma.氧化应激和细胞衰老在代谢相关脂肪性肝病及相关肝细胞癌发病机制中的作用
Antioxidants (Basel). 2023 Jun 14;12(6):1269. doi: 10.3390/antiox12061269.
8
An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians.聚焦非肝硬化性非酒精性脂肪性肝病患者的肝细胞癌监测概述:医师面临的一项挑战
Biomedicines. 2023 Feb 16;11(2):586. doi: 10.3390/biomedicines11020586.
9
Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.非酒精性脂肪性肝炎-肝细胞癌涉及的流行病学、遗传学、致病性、代谢、表观遗传学方面:当前治疗策略
Cancers (Basel). 2022 Dec 20;15(1):23. doi: 10.3390/cancers15010023.
10
The ratio of 12α to non-12-hydroxylated bile acids reflects hepatic triacylglycerol accumulation in high-fat diet-fed C57BL/6J mice.12α-羟化胆汁酸与非 12-羟化胆汁酸的比值反映了高脂肪饮食喂养的 C57BL/6J 小鼠肝三酰甘油的积累。
Sci Rep. 2022 Oct 6;12(1):16707. doi: 10.1038/s41598-022-20838-9.
MAFLD的定义低估了遗传易感性患者发生肝癌的风险。
J Intern Med. 2022 Mar;291(3):374-376. doi: 10.1111/joim.13396. Epub 2021 Oct 3.
4
Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults.膳食模式与美国成年人肝细胞癌风险的关系。
Nutrients. 2021 Jun 11;13(6):2011. doi: 10.3390/nu13062011.
5
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌的流行病学
JHEP Rep. 2021 May 11;3(4):100305. doi: 10.1016/j.jhepr.2021.100305. eCollection 2021 Aug.
6
All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study.所有咖啡类型均可降低慢性肝病不良临床结局的风险:一项英国生物银行研究。
BMC Public Health. 2021 Jun 22;21(1):970. doi: 10.1186/s12889-021-10991-7.
7
Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better.非酒精性脂肪性肝炎(NASH)及NASH诱导的肝细胞癌建模:更快、更优。
Cell Mol Gastroenterol Hepatol. 2021;12(3):1149-1150. doi: 10.1016/j.jcmgh.2021.05.015. Epub 2021 Jun 8.
8
Vitamin D: Possible Therapeutic Roles in Hepatocellular Carcinoma.维生素D:在肝细胞癌中可能的治疗作用
Front Oncol. 2021 May 25;11:642653. doi: 10.3389/fonc.2021.642653. eCollection 2021.
9
Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.非酒精性脂肪性肝炎和 HCC 在多食的 Western 饮食加速的小鼠中发生。
Cell Mol Gastroenterol Hepatol. 2021;12(3):891-920. doi: 10.1016/j.jcmgh.2021.05.010. Epub 2021 May 29.
10
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.非酒精性脂肪性肝炎患者肝细胞癌的分子特征。
J Hepatol. 2021 Oct;75(4):865-878. doi: 10.1016/j.jhep.2021.04.049. Epub 2021 May 13.